{"id":"preparative-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Graft-versus-host disease (GVHD)"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Organ toxicity (hepatic, renal, cardiac, pulmonary)"}]},"_chembl":{"chemblId":"CHEMBL6030155","moleculeType":null,"molecularWeight":"383.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Preparative regimens use high-dose chemotherapy, radiation, or both to eliminate diseased bone marrow cells, suppress the recipient's immune system to prevent graft rejection, and create space for donor stem cells to engraft. The intensity and composition vary based on the underlying disease, donor type, and patient factors, ranging from myeloablative (fully ablative) to reduced-intensity conditioning regimens.","oneSentence":"A preparative regimen is a chemotherapy and/or radiation treatment protocol designed to condition the bone marrow and immune system before hematopoietic stem cell transplantation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:30:03.301Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Conditioning prior to hematopoietic stem cell transplantation for hematologic malignancies"},{"name":"Conditioning prior to hematopoietic stem cell transplantation for severe aplastic anemia"},{"name":"Conditioning prior to hematopoietic stem cell transplantation for inherited bone marrow failure syndromes"}]},"trialDetails":[{"nctId":"NCT02830724","phase":"PHASE1, PHASE2","title":"Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-06","conditions":"Pancreatic Cancer, Renal Cell Cancer, Breast Cancer","enrollment":124},{"nctId":"NCT02621021","phase":"PHASE2","title":"A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-12-04","conditions":"Melanoma","enrollment":170},{"nctId":"NCT06904066","phase":"PHASE1","title":"Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic","enrollment":86},{"nctId":"NCT07328503","phase":"PHASE2","title":"CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Acute Lymphoblastic Leukemia, B-All","enrollment":20},{"nctId":"NCT07493538","phase":"PHASE2","title":"MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases","status":"NOT_YET_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2026-08","conditions":"AML, MDS, Acute Leukemia","enrollment":132},{"nctId":"NCT00576979","phase":"PHASE1, PHASE2","title":"Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2008-03-04","conditions":"Leukemia","enrollment":51},{"nctId":"NCT02133196","phase":"PHASE2","title":"T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-23","conditions":"Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC","enrollment":85},{"nctId":"NCT03412877","phase":"PHASE2","title":"Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-06","conditions":"Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer","enrollment":285},{"nctId":"NCT01861106","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-24","conditions":"GATA2, Immunodeficiency, MDS","enrollment":144},{"nctId":"NCT01890486","phase":"","title":"The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2001-05-21","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia","enrollment":2000},{"nctId":"NCT03745326","phase":"PHASE1, PHASE2","title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-16","conditions":"Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer","enrollment":5},{"nctId":"NCT06865664","phase":"PHASE1","title":"FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-09-22","conditions":"Rhabdomyosarcoma","enrollment":50},{"nctId":"NCT01804634","phase":"PHASE2","title":"Reduced Intensity Haploidentical BMT for High Risk Solid Tumors","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-03-27","conditions":"Refractory and/or Relapsed Metastatic Solid Tumors","enrollment":60},{"nctId":"NCT05442515","phase":"PHASE1, PHASE2","title":"CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-28","conditions":"B-NHL, B-Non Hodgkin Lymphoma, Acute Lymphocytic Leukemia","enrollment":126},{"nctId":"NCT01962636","phase":"NA","title":"Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2016-12","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia","enrollment":200},{"nctId":"NCT02858310","phase":"PHASE1, PHASE2","title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-27","conditions":"Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ","enrollment":224},{"nctId":"NCT01174121","phase":"PHASE2","title":"Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-08-26","conditions":"Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer","enrollment":332},{"nctId":"NCT04195633","phase":"PHASE2","title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-01-25","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT04426669","phase":"PHASE1, PHASE2","title":"A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering","status":"COMPLETED","sponsor":"Intima Bioscience, Inc.","startDate":"2020-05-15","conditions":"Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract","enrollment":23},{"nctId":"NCT05566223","phase":"PHASE1, PHASE2","title":"CISH Inactivated TILs in the Treatment of NSCLC","status":"WITHDRAWN","sponsor":"Intima Bioscience, Inc.","startDate":"2023-02","conditions":"Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT01821781","phase":"PHASE2","title":"Immune Disorder HSCT Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2013-04-29","conditions":"Immune Deficiency Disorders, Severe Combined Immunodeficiency, Chronic Granulomatous Disease","enrollment":20},{"nctId":"NCT00544466","phase":"PHASE1, PHASE2","title":"Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2006-07-31","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":75},{"nctId":"NCT03619551","phase":"PHASE2","title":"Conditioning SCID Infants Diagnosed Early","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2018-10-22","conditions":"SCID","enrollment":56},{"nctId":"NCT05600426","phase":"PHASE3","title":"A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2023-01-25","conditions":"Severe Aplastic Anemia","enrollment":53},{"nctId":"NCT06253520","phase":"PHASE1","title":"Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-16","conditions":"Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer","enrollment":210},{"nctId":"NCT05607095","phase":"PHASE1","title":"A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-11-01","conditions":"Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma","enrollment":30},{"nctId":"NCT04784052","phase":"PHASE1, PHASE2","title":"Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab","status":"RECRUITING","sponsor":"Porteus, Matthew, MD","startDate":"2021-12-07","conditions":"Fanconi Anemia","enrollment":18},{"nctId":"NCT05357027","phase":"PHASE1, PHASE2","title":"HPV16 E6 TCR T Cells for Cervical Carcinoma","status":"TERMINATED","sponsor":"TCRCure Biopharma Ltd.","startDate":"2022-08-10","conditions":"Cervical Carcinoma","enrollment":5},{"nctId":"NCT05868915","phase":"PHASE1","title":"HV-101 for Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Hervor Therapeutics","startDate":"2023-08-04","conditions":"Advanced Solid Tumors","enrollment":1},{"nctId":"NCT06556108","phase":"PHASE1, PHASE2","title":"ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors","status":"COMPLETED","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2018-01-01","conditions":"Advanced Solid Tumors","enrollment":5},{"nctId":"NCT01652092","phase":"NA","title":"Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-09-04","conditions":"SCID, Omenn's Syndrome, Reticular Dysgenesis","enrollment":57},{"nctId":"NCT07288203","phase":"PHASE2","title":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2025-11-28","conditions":"Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma","enrollment":100},{"nctId":"NCT02171104","phase":"PHASE2","title":"MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2014-07-10","conditions":"Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome","enrollment":149},{"nctId":"NCT03128996","phase":"PHASE1, PHASE2","title":"Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-03-20","conditions":"Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders","enrollment":29},{"nctId":"NCT07052370","phase":"PHASE1","title":"TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-09-25","conditions":"Hematologic Malignancy","enrollment":30},{"nctId":"NCT04146298","phase":"PHASE1, PHASE2","title":"Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2021-10-21","conditions":"Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma","enrollment":30},{"nctId":"NCT01319565","phase":"PHASE2","title":"Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-03-24","conditions":"Metastatic Melanoma, Skin Cancer","enrollment":102},{"nctId":"NCT05035407","phase":"PHASE1","title":"T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-08","conditions":"Kita-kyushu Lung Cancer Antigen 1, Human","enrollment":36},{"nctId":"NCT00534469","phase":"PHASE2","title":"Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2000-02-08","conditions":"Leukemia","enrollment":60},{"nctId":"NCT03190941","phase":"PHASE1, PHASE2","title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-09-21","conditions":"Pancreatic Cancer, Gastric Cancer, Gastrointestinal Cancer","enrollment":110},{"nctId":"NCT04232085","phase":"PHASE2","title":"Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-02-12","conditions":"Primary Immune Deficiency Disorder, Immune Deficiency Disease, Bone Marrow Failure","enrollment":27},{"nctId":"NCT05400122","phase":"PHASE1","title":"Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer","status":"SUSPENDED","sponsor":"David Wald","startDate":"2022-09-09","conditions":"Colorectal Cancer, Hematologic Malignancy, Rectum Cancer","enrollment":12},{"nctId":"NCT06195891","phase":"PHASE1","title":"Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-05-24","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":33},{"nctId":"NCT03670966","phase":"PHASE1, PHASE2","title":"211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-07-10","conditions":"Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission","enrollment":30},{"nctId":"NCT02250937","phase":"PHASE2","title":"Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-10-27","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":116},{"nctId":"NCT06358638","phase":"PHASE2","title":"Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody","status":"RECRUITING","sponsor":"Children's National Research Institute","startDate":"2024-04-03","conditions":"Sickle Cell Disease","enrollment":12},{"nctId":"NCT06690281","phase":"PHASE2","title":"A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2025-09-09","conditions":"Gastrointestinal Carcinoma, Pancreatic Cancer, Hepatocellular Cancer","enrollment":""},{"nctId":"NCT01385423","phase":"PHASE1","title":"Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-09","conditions":"Acute Myelogenous Leukemia, Myelodysplastic Syndrome","enrollment":26},{"nctId":"NCT05881525","phase":"PHASE1","title":"NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"TCRCure Biopharma Ltd.","startDate":"2023-06-01","conditions":"Advanced Solid Tumors","enrollment":18},{"nctId":"NCT03467516","phase":"PHASE2","title":"Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma","status":"RECRUITING","sponsor":"Udai Kammula","startDate":"2018-05-14","conditions":"Uveal Neoplasms, Melanoma, Uveal","enrollment":47},{"nctId":"NCT03801083","phase":"PHASE2","title":"Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers","status":"RECRUITING","sponsor":"Udai Kammula","startDate":"2019-02-19","conditions":"Biliary Tract Cancer, Cholangiocarcinoma, Biliary Tract Neoplasms","enrollment":59},{"nctId":"NCT03935893","phase":"PHASE2","title":"Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers","status":"RECRUITING","sponsor":"Udai Kammula","startDate":"2019-12-03","conditions":"Gastric Cancer, Colorectal Cancer, Pancreatic Cancer","enrollment":240},{"nctId":"NCT02722668","phase":"PHASE2","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-05-15","conditions":"Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma","enrollment":15},{"nctId":"NCT03597594","phase":"PHASE1, PHASE2","title":"Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-09-02","conditions":"Severe Combined Immunodeficiency","enrollment":4},{"nctId":"NCT01430390","phase":"PHASE1","title":"In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-09","conditions":"Acute Lymphocytic Leukemia, Lymphoma","enrollment":19},{"nctId":"NCT06190249","phase":"PHASE1","title":"Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma","status":"WITHDRAWN","sponsor":"James Isaacs, MD","startDate":"2024-12-02","conditions":"Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IIID Melanoma","enrollment":""},{"nctId":"NCT06680661","phase":"PHASE2","title":"ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis","status":"RECRUITING","sponsor":"Leland Metheny","startDate":"2025-02-25","conditions":"Acute Myelogenous Leukemia, Acute Lymphatic Leukemia, Chronic Myelogenous Leukemia","enrollment":20},{"nctId":"NCT00534430","phase":"PHASE2","title":"Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2000-02-29","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":30},{"nctId":"NCT01350232","phase":"NA","title":"Treatment of Sickle Cell Anemia With Stem Cell Transplant","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2009-09","conditions":"Sickle Cell Anemia, Sickle Cell-hemoglobin C Disease, Sickle Cell-β0-thalassemia","enrollment":2},{"nctId":"NCT01054196","phase":"PHASE1, PHASE2","title":"Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2010-08","conditions":"Multiple Myeloma","enrollment":52},{"nctId":"NCT02845596","phase":"NA","title":"Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Michael Pulsipher","startDate":"2016-08","conditions":"Severe Aplastic Anemia","enrollment":40},{"nctId":"NCT02162420","phase":"NA","title":"Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2015-01-10","conditions":"Dyskeratosis Congenita, Aplastic Anemia","enrollment":61},{"nctId":"NCT03417284","phase":"PHASE1, PHASE2","title":"Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-09","conditions":"Plasma Cell Myeloma","enrollment":62},{"nctId":"NCT02766465","phase":"PHASE2","title":"Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-03-16","conditions":"Sickle Cell Disease","enrollment":138},{"nctId":"NCT06803745","phase":"NA","title":"Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-03-27","conditions":"Acute Leukemia, Acute Lymphoblastic Lymphoma","enrollment":160},{"nctId":"NCT04337515","phase":"NA","title":"A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant","status":"RECRUITING","sponsor":"Christopher Dvorak","startDate":"2019-12-19","conditions":"Graft Vs Host Disease, Graft-versus-host-disease","enrollment":90},{"nctId":"NCT01163357","phase":"PHASE1","title":"Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2011-01-28","conditions":"Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia","enrollment":18},{"nctId":"NCT01758328","phase":"PHASE1","title":"Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Multiple Myeloma","enrollment":29},{"nctId":"NCT00719888","phase":"PHASE2","title":"Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2005-11-18","conditions":"Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":135},{"nctId":"NCT02179359","phase":"NA","title":"Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2014-09-02","conditions":"Sickle Cell Disease, Transfusion Dependent Alpha- or Beta- Thalassemia, Diamond Blackfan Anemia","enrollment":38},{"nctId":"NCT01701986","phase":"PHASE1, PHASE2","title":"Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-10-25","conditions":"Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":64},{"nctId":"NCT05298358","phase":"PHASE1","title":"RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-11-18","conditions":"Systemic Sclerosis","enrollment":1},{"nctId":"NCT05141474","phase":"EARLY_PHASE1","title":"Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors","status":"RECRUITING","sponsor":"Vall d'Hebron Institute of Oncology","startDate":"2021-10-28","conditions":"Epithelial Tumors, Malignant, Malignant Solid Tumor","enrollment":10},{"nctId":"NCT03919240","phase":"PHASE1, PHASE2","title":"CAR-T Cell Therapy Targeting to CD19 for R/R ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2015-12-01","conditions":"Acute Lymphoblastic Leukemia with Failed Remission","enrollment":196},{"nctId":"NCT05951153","phase":"EARLY_PHASE1","title":"Tributyrin to Promote Gut Health Among Children Undergoing Hematopoietic Cell Transplantation","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2024-08-01","conditions":"Hematopoietic Cell Transplantation (HCT)","enrollment":""},{"nctId":"NCT03539406","phase":"PHASE1","title":"Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2019-06-04","conditions":"Recurrent Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma","enrollment":11},{"nctId":"NCT04808167","phase":"NA","title":"Remote Ischemic Conditioning in HSCT","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-08-21","conditions":"Hematopoietic Stem Cell Transplantations","enrollment":17},{"nctId":"NCT05711628","phase":"PHASE3","title":"A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT01081405","phase":"NA","title":"Total Lymphoid Irradiation and Anti-Thymocyte Globulin in the Allogeneic Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2007-11","conditions":"HEMATOLOGIC MALIGNANCIES","enrollment":20},{"nctId":"NCT04102436","phase":"PHASE2","title":"Non-Viral TCR Gene Therapy","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2024-03-08","conditions":"Endocrine/Neuroendocrine, Non-Small Cell Lung Cancer, Breast Cancer","enrollment":""},{"nctId":"NCT01041508","phase":"PHASE1","title":"Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.","status":"COMPLETED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2010-01-29","conditions":"Leukemia Lymphoblastic, Acute, Acute Myeloid Leukemia, Neoplasm Recurrent","enrollment":18},{"nctId":"NCT03068624","phase":"PHASE1","title":"Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma","status":"UNKNOWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-09-08","conditions":"Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma","enrollment":34},{"nctId":"NCT01898793","phase":"PHASE1, PHASE2","title":"Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2014-08-11","conditions":"Leukemia, Myeloid, Acute","enrollment":89},{"nctId":"NCT02917096","phase":"PHASE1","title":"Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2016-11-13","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":18},{"nctId":"NCT01092026","phase":"NA","title":"Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2010-11","conditions":"Allogeneic Stem Cell Transplantation","enrollment":11},{"nctId":"NCT00540995","phase":"PHASE1, PHASE2","title":"Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer","status":"TERMINATED","sponsor":"City of Hope Medical Center","startDate":"2007-06-11","conditions":"Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)","enrollment":25},{"nctId":"NCT00047060","phase":"PHASE1, PHASE2","title":"Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2002-07-30","conditions":"Mycosis Fungoides, Sezary Syndrome","enrollment":5},{"nctId":"NCT00167219","phase":"PHASE1, PHASE2","title":"Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"1999-11-18","conditions":"Juvenile Myelomonocytic Leukemia","enrollment":15},{"nctId":"NCT02757885","phase":"PHASE2","title":"Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-07-10","conditions":"Sickle Cell Disease","enrollment":10},{"nctId":"NCT02248597","phase":"PHASE2","title":"Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2015-02-25","conditions":"Graft Versus Host Disease, Hematopoietic/Lymphoid Cancer","enrollment":27},{"nctId":"NCT01035463","phase":"PHASE1, PHASE2","title":"Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2009-11-12","conditions":"Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma","enrollment":74},{"nctId":"NCT01336933","phase":"PHASE2","title":"Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2011-07-06","conditions":"Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma","enrollment":34},{"nctId":"NCT02661035","phase":"PHASE2","title":"Allo HSCT Using RIC for Hematological Diseases","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-03-09","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia","enrollment":156},{"nctId":"NCT00003838","phase":"PHASE2","title":"Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-04-15","conditions":"Myeloproliferative Disorders, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia","enrollment":202},{"nctId":"NCT03050216","phase":"PHASE2","title":"QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-05-16","conditions":"Acute Myeloid Leukemia","enrollment":8},{"nctId":"NCT00045305","phase":"PHASE2","title":"Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2006-10-24","conditions":"Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms","enrollment":17},{"nctId":"NCT00796068","phase":"PHASE2","title":"Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-02-24","conditions":"Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission","enrollment":130},{"nctId":"NCT02743351","phase":"PHASE1, PHASE2","title":"Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Fate Therapeutics","startDate":"2016-12-20","conditions":"Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia","enrollment":96},{"nctId":"NCT01993719","phase":"PHASE2","title":"Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-12-12","conditions":"Metastatic Melanoma","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1076,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fludara","Cytoxan","radiation"],"phase":"phase_3","status":"active","brandName":"Preparative regimen","genericName":"Preparative regimen","companyName":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","companyId":"federal-research-institute-of-pediatric-hematology-oncology-and-immunology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A preparative regimen is a chemotherapy and/or radiation treatment protocol designed to condition the bone marrow and immune system before hematopoietic stem cell transplantation. Used for Conditioning prior to hematopoietic stem cell transplantation for hematologic malignancies, Conditioning prior to hematopoietic stem cell transplantation for severe aplastic anemia, Conditioning prior to hematopoietic stem cell transplantation for inherited bone marrow failure syndromes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}